ArticlePhilosophical transactions of the Royal Society of London. Series B, Biological sciences2015
How could preventive therapy affect the prevalence of drug resistance? Causes and consequences.
Article in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Interventions for the prevention of recurrent erysipelas and cellulitis.The Cochrane database of systematic reviews · 2017Pooled it
- Tuberculosis prevention: current strategies and future directions.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2024Review
- Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania.The Lancet. Global health · 2022Article
- Burden of Antimicrobial Resistance: Compared to What?Epidemiologic reviews · 2022Article
- Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.BMC medicine · 2021Article
- Novel anti-malarial drug strategies to prevent artemisinin partner drug resistance: A model-based analysis.PLoS computational biology · 2021Article
- Choosing interventions to eliminate forest malaria: preliminary results of two operational research studies inside Cambodian forests.Malaria journal · 2021Article
- Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.Clinical microbiology reviews · 2018Review
- malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication.PLoS medicine · 2017Review
- Displacement of sexual partnerships in trials of sexual behavior interventions: A model-based assessment of consequences.Epidemics · 2017Article
- Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers.Antimicrobial agents and chemotherapy · 2017Article
- Why does drug resistance readily evolve but vaccine resistance does not?Proceedings. Biological sciences · 2017Review
- Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.AIDS (London, England) · 2016Article
- Antimicrobial resistance: addressing the threat to global health. Preface.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Various forms of preventive and prophylactic antimicrobial therapies have been proposed to combat HIV (e.g. pre-exposure prophylaxis), tuberculosis (e.g. isoniazid preventive therapy) and malaria (e.g. intermittent preventive treatment). However, the potential population-level effects of preventative therapy (PT) on the prevalence of drug resistance are not well understood. PT can directly affect the rate at which resistance is acquired among those receiving PT. It can also indirectly affect resistance by altering the rate at which resistance is acquired through treatment for active disease and by modifying the level of competition between transmission of drug-resistant and drug-sensitive pathogens. We propose a general mathematical model to explore the ways in which PT can affect the long-term prevalence of drug resistance. Depending on the relative contributions of these three mechanisms, we find that increasing the level of coverage of PT may result in increases, decreases or non-monotonic changes in the overall prevalence of drug resistance. These results demonstrate the complexity of the relationship between PT and drug resistance in the population. Care should be taken when predicting population-level changes in drug resistance from small pilot studies of PT or estimates based solely on its direct effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.